Curevac NV

BioNTech SE announced the successful satisfaction of the minimum condition for its exchange offer for CureVac N.V., with 81.74% of shares tendered.

BioNTech announced CureVac shareholders overwhelmingly approved its exchange offer, setting the stage for the acquisition's completion with a defined exchange ratio.

BioNTech's third-quarter revenue surged 22% driven by a significant out-licensing deal with Bristol-Myers Squibb, despite a decline in COVID-19 vaccine sales and a confirmed full-year net loss outlook.

BioNTech SE reports narrower net losses for the nine months ended September 30, 2025, driven by out-licensing revenue, while progressing its public exchange offer for CureVac N.V. shares.

BioNTech SE has initiated an exchange offer to acquire all outstanding shares of CureVac N.V., as detailed in its recent SEC filing.

BioNTech SE has commenced its public exchange offer to acquire all outstanding shares of CureVac N.V. for an implied aggregate equity value of approximately $1.25 billion, aiming to bolster its mRNA-based cancer immunotherapy pipeline.

MH-LT-Investments GmbH and Dr. Matthias Hothum have completed the exchange of all their CureVac N.V. shares for BioNTech SE securities, marking their exit as beneficial owners.

A group of reporting persons, including dievini Hopp BioTech holding GmbH & Co. KG, has completed the tender of all their CureVac N.V. shares to BioNTech SE through an exchange offer.

KfW has completed the tender of all its Common Shares in CureVac N.V. through an Exchange Offer, resulting in 0% beneficial ownership and the expected termination of the Shareholders' Agreement.

GSK plc has finalized the sale of all its common shares in CureVac N.V. through a recent Exchange Offer.

GSK plc's subsidiary, Glaxo Group Limited, has agreed to tender its 7.4% stake in CureVac N.V. into BioNTech SE's exchange offer.

Germany's state-owned KfW bank has agreed to tender its significant stake in CureVac N.V. to BioNTech SE, supporting an exchange offer that aims to acquire all outstanding shares and facilitate a post-offer reorganization.